Latest news with #ZimmerBiomet
Yahoo
7 hours ago
- Business
- Yahoo
Zimmer Biomet Holdings (NYSE:ZBH) Declares US$0.24 Quarterly Dividend for Q2 2025
Zimmer Biomet Holdings announced the approval of a quarterly cash dividend of $0.24 per share, payable later this year. Over the past week, the company's share price increased by 2%, a move that aligns with the broader market, which rose by 1%. This dividend affirmation might have provided some stability amid market fluctuations affected by broader economic news, such as concerns over U.S.-China trade relations. While the S&P 500 and Nasdaq saw dips due to market uncertainties, Zimmer Biomet's announcement likely served as a minor positive reinforcement for its stockholders. We've discovered 1 weakness for Zimmer Biomet Holdings that you should be aware of before investing here. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The announcement of Zimmer Biomet Holdings' quarterly cash dividend aligns with its ongoing revenue growth efforts in the U.S. hip and knee markets. The dividend, alongside innovative product introductions like the Z1 hip stem and Persona OsseoTi knee, might enhance investor confidence in the company's strategic focus on capturing competitive accounts and increasing market share. Furthermore, the successful integration of the Paragon 28 acquisition may significantly contribute to future earnings and revenue synergies, providing a foundation for anticipated growth despite macroeconomic challenges. Over the past year, Zimmer Biomet's total shareholder return, combining share price movement and dividend payout, declined by 17.71%. This underperformance stands in stark contrast to the U.S. Medical Equipment industry, which returned 9.6% over the same period. This divergence highlights ongoing challenges, yet the dividend payout suggests some underlying stability may be supporting investor sentiment. The company's recent share price of US$92.27 remains below the analysts' consensus price target of US$110.2, representing a potential upside of 16.3%. This gap may suggest market caution over tariff impacts and integration costs, but it also indicates confidence in the company's long-term growth strategy. Revenue and earnings forecasts, with expected revenue reaching US$9.0 billion by 2028 and earnings of US$1.3 billion, reinforce the potential for improved financial performance, albeit contingent on successful execution and the management of external pressures. As the company navigates these dynamics, shareholder insights will be crucial in shaping long-term valuation coverage. Navigate through the intricacies of Zimmer Biomet Holdings with our comprehensive balance sheet health report here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ZBH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
9 hours ago
- Business
- Yahoo
Zimmer Biomet Holdings (NYSE:ZBH) Declares US$0.24 Quarterly Dividend for Q2 2025
Zimmer Biomet Holdings announced the approval of a quarterly cash dividend of $0.24 per share, payable later this year. Over the past week, the company's share price increased by 2%, a move that aligns with the broader market, which rose by 1%. This dividend affirmation might have provided some stability amid market fluctuations affected by broader economic news, such as concerns over U.S.-China trade relations. While the S&P 500 and Nasdaq saw dips due to market uncertainties, Zimmer Biomet's announcement likely served as a minor positive reinforcement for its stockholders. We've discovered 1 weakness for Zimmer Biomet Holdings that you should be aware of before investing here. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The announcement of Zimmer Biomet Holdings' quarterly cash dividend aligns with its ongoing revenue growth efforts in the U.S. hip and knee markets. The dividend, alongside innovative product introductions like the Z1 hip stem and Persona OsseoTi knee, might enhance investor confidence in the company's strategic focus on capturing competitive accounts and increasing market share. Furthermore, the successful integration of the Paragon 28 acquisition may significantly contribute to future earnings and revenue synergies, providing a foundation for anticipated growth despite macroeconomic challenges. Over the past year, Zimmer Biomet's total shareholder return, combining share price movement and dividend payout, declined by 17.71%. This underperformance stands in stark contrast to the U.S. Medical Equipment industry, which returned 9.6% over the same period. This divergence highlights ongoing challenges, yet the dividend payout suggests some underlying stability may be supporting investor sentiment. The company's recent share price of US$92.27 remains below the analysts' consensus price target of US$110.2, representing a potential upside of 16.3%. This gap may suggest market caution over tariff impacts and integration costs, but it also indicates confidence in the company's long-term growth strategy. Revenue and earnings forecasts, with expected revenue reaching US$9.0 billion by 2028 and earnings of US$1.3 billion, reinforce the potential for improved financial performance, albeit contingent on successful execution and the management of external pressures. As the company navigates these dynamics, shareholder insights will be crucial in shaping long-term valuation coverage. Navigate through the intricacies of Zimmer Biomet Holdings with our comprehensive balance sheet health report here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ZBH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025
WARSAW, Ind., May 30, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2025. The cash dividend of $0.24 per share is payable on or about July 31, 2025 to stockholders of record as of the close of business on June 26, 2025. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit or follow on LinkedIn at or X / Twitter at Media Investors Heather Zoumas-Lubeski David DeMartino 445-248-0577 646-531-6115 Weiner 908-591-6955 View original content to download multimedia: SOURCE Zimmer Biomet Holdings, Inc.
Yahoo
2 days ago
- Business
- Yahoo
Zimmer Biomet Chairman, President and CEO Ivan Tornos Joins OREF Board of Trustees
ROSEMONT, Ill., May 29, 2025 /PRNewswire/ -- The Orthopaedic Research and Education Foundation (OREF), the leading private nonprofit organization funding musculoskeletal (MSK) research across all orthopaedic sub-specialties, is pleased to announce that Ivan Tornos, Chairman, President and CEO of orthopaedic medical device company Zimmer Biomet has joined its Board of Trustees. Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics. Prior to his appointment as President and Chief Executive Officer in 2023, he held the positions of Group President, Global Businesses and the Americas, and Chief Operating Officer with responsibility for overseeing all global businesses at Zimmer Biomet. He was elected Chairman of the Board of Directors of Zimmer Biomet, a global leader in musculoskeletal health, in May of 2025. OREF Board President, Joshua J. Jacobs, MD, stated, "On behalf of the entire board, I am delighted to welcome Ivan to OREF. Our two organizations have a long history of collaboration and a shared commitment to improving patient care and outcomes. Ivan's presence on the OREF board will bring heightened visibility to our mission and to the need for more research funding. His service to OREF and the financial support of Zimmer Biomet underscore his commitment to improving the health of our communities here in the U.S. and throughout the world." "I am thrilled to be joining the OREF board. Now more than ever, it's important we move with a sense of urgency and deep purpose to ensure that musculoskeletal research advances at a much faster pace and delivers even bolder solutions. There are countless patients currently waiting on the sidelines who could benefit from the meaningful work that we will do together, and I'm committed to doing all I can to reduce the current gaps in this area," said Ivan Tornos. The growing burden of MSK conditions in the United States is well documented with MSK-related diseases and injuries affecting more than half of the adult population and imposing an estimated economic burden of $980 billion annually.1 Despite the outsized impact of MSK diseases on quality of life and the U.S. economy, funding for MSK conditions is disproportionately low when comparing the physical and economic burden of various diseases. OREF is a leading voice in advocating for increased MSK research funding and strongly believes that the nation's healthcare will not improve unless and until MSK research funding becomes a national priority. OREF grantees' success in securing additional funding from the NIH and other government entities is unparalleled within the MSK research community. Research published in JBJS demonstrates that OREF grant recipients are more likely to receive subsequent NIH funding compared to other applicants (23.5 percent vs. 20.6 percent), with Career Development Grant recipients achieving a 48.4 percent success rate.2 Given the limited availability of MSK research funds, investing in a reputable independent source with a proven return on investment is essential. OREF's collaboration with more than 60 MSK-related organizations is a key factor in its success in funding significant and impactful research that improves clinical practice and patient outcomes. About OREF An independent 501(c)3 nonprofit, OREF strives to improve clinical care and patient outcomes by advancing innovative research, developing new investigators, and uniting the orthopaedic community in promoting musculoskeletal health. The Foundation raises funds to support research on diseases and injuries of bones, nerves, muscles, and tendons and to enhance clinical care leading to improved health, increased activity, and a better quality of life for patients. For more information, visit or follow OREF on X and LinkedIn. 1United States Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States (BMUS), Third Edition, 2014. Rosemont, IL. Available at 2Li, Alan K. BS1,a; Kendal, Joseph K. MD, MSc2; Hamad, Christopher D. MD2; Peterson, Nicholas V. MD2; Asachi, Parsa BA1; Taylor, Jeremiah M. BS1; Le, Michael M. MD1; Lloyd, Trevor S. BS1; Wessel, Lauren E. MD2; Bernthal, Nicholas M. MD2. Identifying Predictors of Successful Conversion from OREF Grants to Extramural Federal Funding Among Orthopaedic Surgeons. The Journal of Bone and Joint Surgery 107(1):p 96-103, January 1, 2025. DOI: 10.2106/JBJS.24.0064 View original content to download multimedia: SOURCE Orthopaedic Research and Education Foundation
Yahoo
2 days ago
- Business
- Yahoo
Zimmer hires former Nevro CEO Kevin Thornal
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Kevin Thornal New title: Group president for global businesses and the Americas, Zimmer Biomet Previous title: President and CEO, Nevro Zimmer Biomet named Kevin Thornal to the newly created position of group president for global businesses and the Americas, effective July 1, the orthopedics device maker said Tuesday. Thornal was president and CEO of spinal cord stimulation company Nevro from April 2023 until it was acquired by Globus Medical last month for about $250 million. Before that, he was group president of global diagnostic solutions at Hologic, where he held a series of leadership positions beginning in 2014. Before joining Hologic, Thornal worked in sales, marketing and business development at Stryker for 10 years, including as head of North American sales for its interventional spine business. In his new role, Thornal will oversee the Americas commercial organization and lead business strategy and execution for the global knees, hips, S.E.T. and data, technology and enabling solutions units. Thornal will receive an annual base salary of $850,000, with a bonus opportunity in 2025 equal to 100% of his salary on a prorated basis, if performance goals are achieved, Zimmer said in a securities filing. He will also receive restricted stock units valued at $2.65 million and performance-based restricted stock units valued at $2.65 million. In connection with Thornal's appointment, Mark Bezjak will remain president of the Americas but will no longer be an executive officer, according to the filing. Bezjak was promoted to president of the Americas from president of North America in September 2023, shortly after CEO Ivan Tornos became Zimmer's top executive.
